Cardiovascular Prevention and Pharmacotherapy最新文献_第2页

Correlation analysis of cancer incidence after pravastatin treatment 普伐他汀治疗后肿瘤发病率的相关分析

Cardiovascular Prevention and Pharmacotherapy Pub Date : 2023-04-30 DOI: 10.36011/cpp.2023.5.e6

Jin Yu, R. Kim, Jiwon Shinn, Man-Young Park, Hun‐Sung Kim

{"title":"Correlation analysis of cancer incidence after pravastatin treatment","authors":"Jin Yu, R. Kim, Jiwon Shinn, Man-Young Park, Hun‐Sung Kim","doi":"10.36011/cpp.2023.5.e6","DOIUrl":"https://doi.org/10.36011/cpp.2023.5.e6","url":null,"abstract":"Background: Few studies have investigated the cancer-preventive effects of statins, which are known to protect against cardio-cerebrovascular diseases. In this study, we analyzed the degree to which pravastatin, a low-potency statin, could prevent cancer.Methods: This retrospective cohort study used data from the Korean National Health Insurance Service database. Patients diagnosed with diabetes after the age of 50 years were divided into a pravastatin group and a control group that did not receive any statin prescriptions.Results: This study included 557 patients in the pravastatin group and 2,221 patients in the control (no statin) group. During the 5-year follow-up, the incidence of cancer was 16.7% (93 of 557 patients) in the pravastatin group and 19.9% (442 of 2,221 patients) in the control group. The incidence of cancer was 22% higher in the control group than in the pravastatin group (hazard ratio, 1.22; 95% confidence interval, 0.97–1.52; P=0.09). Death from various causes occurred at a 45% higher frequency in the control group than in the pravastatin group (hazard ratio, 1.45; 95% confidence interval, 0.99–2.12; P=0.06). However, neither of those relationships reached statistical significance.Conclusions: Although pravastatin use did not show a significant causal relationship with cancer incidence, fewer cases of cancer occurred in pravastatin users than in controls. However, further large-scale studies are required to confirm these findings.","PeriodicalId":348697,"journal":{"name":"Cardiovascular Prevention and Pharmacotherapy","volume":"93 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123982678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research on obesity using the National Health Information Database: recent trends 使用国家健康信息数据库的肥胖研究:最近的趋势

Cardiovascular Prevention and Pharmacotherapy Pub Date : 2023-04-30 DOI: 10.36011/cpp.2023.5.e8

E. Rhee

引用次数: 0

Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice 利拉鲁肽，一种胰高血糖素样肽-1类似物，在肥胖患者的临床应用

Cardiovascular Prevention and Pharmacotherapy Pub Date : 2023-04-30 DOI: 10.36011/cpp.2023.5.e7

Juyoung Shin, Ra-Jeong Kim, Hun‐Sung Kim

引用次数: 0

Optimal target blood pressure in older patients with hypertension 老年高血压患者的最佳目标血压

Cardiovascular Prevention and Pharmacotherapy Pub Date : 2023-04-24 DOI: 10.36011/cpp.2023.5.e4

Kwang-il Kim

引用次数: 0

Fabry disease screening in young patients with acute ischemic stroke in Korea 韩国年轻急性缺血性脑卒中患者法布里病筛查

Cardiovascular Prevention and Pharmacotherapy Pub Date : 2023-04-24 DOI: 10.36011/cpp.2023.5.e5

Yunjung Choi, Taedong Ok, K. Lee

引用次数: 0

Modifiable risk factors for coronary artery disease in the Indonesian population: a nested case-control study 印度尼西亚人群冠状动脉疾病的可改变危险因素:一项巢式病例对照研究

Cardiovascular Prevention and Pharmacotherapy Pub Date : 2023-01-31 DOI: 10.36011/cpp.2023.5.e3

A. B. Hartopo, M. P. Inggriani, B. W. Jhundy, J. Fachiroh, P. T. Rosha, R. K. Wardani, F. Dewi

{"title":"Modifiable risk factors for coronary artery disease in the Indonesian population: a nested case-control study","authors":"A. B. Hartopo, M. P. Inggriani, B. W. Jhundy, J. Fachiroh, P. T. Rosha, R. K. Wardani, F. Dewi","doi":"10.36011/cpp.2023.5.e3","DOIUrl":"https://doi.org/10.36011/cpp.2023.5.e3","url":null,"abstract":"Background: There is a lack of data on modifiable coronary artery disease (CAD) risk factors in the Indonesian population, hindering the implementation of assessments and prevention programs in this population. This study investigated modifiable risk factors for CAD among Indonesians by comparing them between CAD-proven patients and healthy subjects from a similar population. Methods: In this nested, matched case-control study, the cases were patients from a referral hospital in Yogyakarta, Indonesia and the controls were respondents in a population surveillance system in Yogyakarta, Indonesia. The cases were 421 patients who had undergone coronary angiography, showing significant CAD. The sex- and age-matched controls were 842 respondents from the Universitas Gadjah Mada Health and Health and Demographic Surveillance System Sleman who indicated no CAD presence on a questionnaire. The modifiable CAD risk factors compared between cases and controls were diabetes mellitus, hypertension, central obesity, smoking history, physical inactivity, and less fruit and vegetable intake. A multivariate regression model was applied to determine independent modifiable risk factors for CAD, expressed as adjusted odds ratios (AORs).Results: A multivariate analysis model of 1,263 subjects including all modifiable risk factors indicated that diabetes mellitus (AOR, 3.32; 95% confidence interval [CI], 2.09–5.28), hypertension (AOR, 2.52; 95% CI, 1.76–3.60), former smoking (AOR, 4.18; 95% CI, 2.73–6.39), physical inactivity (AOR, 15.91; 95% CI, 10.13–24.99), and less fruit and vegetable intake (AOR, 5.42; 95% CI, 2.84–10.34) independently and significantly emerged as risk factors for CAD.Conclusions: Hypertension, diabetes mellitus, former smoking, physical inactivity, and less fruit and vegetable intake were independent and significant modifiable risk factors for CAD in the Indonesian population.","PeriodicalId":348697,"journal":{"name":"Cardiovascular Prevention and Pharmacotherapy","volume":"66 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126883527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Changes in cardiovascular-related health behaviors during the COVID-19 pandemic COVID-19大流行期间心血管相关健康行为的变化

Cardiovascular Prevention and Pharmacotherapy Pub Date : 2023-01-27 DOI: 10.36011/cpp.2023.5.e2

Eunji Kim, C. Jung, D. Kim, S. Ko, Hae-Young Lee, K. Lee, Dae-Ryong Kang, S. Ryu, Won-Young Lee, E. Rhee, H. Kim

引用次数: 1

Adverse reactions to antiarrhythmic drugs 抗心律失常药物的不良反应

Cardiovascular Prevention and Pharmacotherapy Pub Date : 2023-01-16 DOI: 10.36011/cpp.2023.5.e1

Ungjeong Do

引用次数: 0

Metabolically healthy obesity: it is time to consider its dynamic changes 代谢健康型肥胖:是时候考虑它的动态变化了

Cardiovascular Prevention and Pharmacotherapy Pub Date : 2022-10-31 DOI: 10.36011/cpp.2022.4.e19

Y. Cho, C. Jung

{"title":"Metabolically healthy obesity: it is time to consider its dynamic changes","authors":"Y. Cho, C. Jung","doi":"10.36011/cpp.2022.4.e19","DOIUrl":"https://doi.org/10.36011/cpp.2022.4.e19","url":null,"abstract":"Obesity reduces life expectancy, lowers quality of life, and causes numerous cardiometabolic diseases and some cancers. However, the individual risk of developing obesity-associated comorbidities is highly variable and cannot be explained only by body mass index. Observations that some obese people have a low risk for cardiometabolic disorders gave rise to the notion of metabolically healthy obesity (MHO). Despite the lack of a precise definition, MHO is typically identified by normal glucose and lipid metabolism indices, as well as the absence of hypertension. In individuals with MHO, the absence of metabolic abnormalities may minimize the risk of mortality, cardiovascular diseases, chronic kidney disease, dementia, and cancer, compared to metabolically unhealthy individuals with obesity. However, MHO appears to be a temporary phenotype that may not confer permanent benefits to individuals with obesity, further justifying therapeutic efforts to maintain metabolic fitness. In this review, we describe the traits of the MHO phenotype, its changeable nature, and the factors associated with phenotype change. In addition, we discuss the clinical outcomes of the MHO phenotype, particularly focusing on the transition of metabolic health over time and its effect on cardiometabolic disorders. Finally, the clinical importance of maintaining metabolic health is emphasized.","PeriodicalId":348697,"journal":{"name":"Cardiovascular Prevention and Pharmacotherapy","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124905698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effects and side effects of liraglutide as a treatment for obesity 利拉鲁肽治疗肥胖症的效果和副作用

Cardiovascular Prevention and Pharmacotherapy Pub Date : 2022-10-31 DOI: 10.36011/cpp.2022.4.e18

J. Ha, Jin Yu, Joonyub Lee, Hun‐Sung Kim

引用次数: 0